Your browser doesn't support javascript.
loading
Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia.
Das, Shampa; Fitzgerald, Richard; Ullah, Asad; Bula, Marcin; Collins, Andrea M; Mitsi, Elena; Reine, Jesus; Hill, Helen; Rylance, Jamie; Ferreira, Daniela M; Tripp, Karen; Bertasini, Andrea; Franzoni, Samantha; Massimiliano, Mameli; Lahlou, Omar; Motta, Paola; Barth, Philip; Velicitat, Patrick; Knechtle, Philipp; Hope, William.
Afiliação
  • Das S; Antimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool Health Partners, Liverpool, United Kingdom.
  • Fitzgerald R; Liverpool University Hospital Foundation Trust, Liverpool Health Partners, Liverpool, United Kingdom.
  • Ullah A; Liverpool University Hospital Foundation Trust, Liverpool Health Partners, Liverpool, United Kingdom.
  • Bula M; Liverpool University Hospital Foundation Trust, Liverpool Health Partners, Liverpool, United Kingdom.
  • Collins AM; Liverpool University Hospital Foundation Trust, Liverpool Health Partners, Liverpool, United Kingdom.
  • Mitsi E; Liverpool School of Tropical Medicine, Liverpool Health Partners, Liverpool, United Kingdom.
  • Reine J; Liverpool School of Tropical Medicine, Liverpool Health Partners, Liverpool, United Kingdom.
  • Hill H; Liverpool School of Tropical Medicine, Liverpool Health Partners, Liverpool, United Kingdom.
  • Rylance J; Liverpool School of Tropical Medicine, Liverpool Health Partners, Liverpool, United Kingdom.
  • Ferreira DM; Liverpool University Hospital Foundation Trust, Liverpool Health Partners, Liverpool, United Kingdom.
  • Tripp K; Liverpool School of Tropical Medicine, Liverpool Health Partners, Liverpool, United Kingdom.
  • Bertasini A; Liverpool School of Tropical Medicine, Liverpool Health Partners, Liverpool, United Kingdom.
  • Franzoni S; Liverpool University Hospital Foundation Trust, Liverpool Health Partners, Liverpool, United Kingdom.
  • Massimiliano M; Aptuit (Verona) Srl, an Evotec Company, Verona, Italy.
  • Lahlou O; Aptuit (Verona) Srl, an Evotec Company, Verona, Italy.
  • Motta P; Aptuit (Verona) Srl, an Evotec Company, Verona, Italy.
  • Barth P; Allecra Therapeutics SAS, St-Louis, France.
  • Velicitat P; Allecra Therapeutics SAS, St-Louis, France.
  • Knechtle P; Allecra Therapeutics SAS, St-Louis, France.
  • Hope W; Allecra Therapeutics SAS, St-Louis, France.
Article em En | MEDLINE | ID: mdl-33077666
ABSTRACT
Cefepime-enmetazobactam is a novel ß-lactam-ß-lactamase inhibitor combination with broad-spectrum antimicrobial activity against a range of multidrug-resistant Enterobacteriaceae This agent is being developed for a range of serious hospital infections. An understanding of the extent of partitioning of ß-lactam-ß-lactamase inhibitor combinations into the human lung is required to better understand the potential role of cefepime-enmetazobactam for the treatment of nosocomial pneumonia. A total of 20 healthy volunteers were used to study the intrapulmonary pharmacokinetics of a regimen of 2 g cefepime-1 g enmetazobactam every 8 h intravenously (2 g/1 g q8h i.v.). Each volunteer contributed multiple plasma samples and a single epithelial lining fluid (ELF) sample, obtained by bronchoalveolar lavage. Concentrations of cefepime and enmetazobactam were quantified using liquid chromatography-tandem mass spectrometry. The pharmacokinetic data were modeled using a population methodology, and Monte Carlo simulations were performed to assess the attainment of pharmacodynamic targets defined in preclinical models. The concentration-time profiles of both agents in plasma and ELF were similar. The mean ± standard deviation percentage of partitioning of total drug concentrations of cefepime and enmetazobactam between plasma and ELF was 60.59% ± 28.62% and 53.03% ± 21.05%, respectively. Using pharmacodynamic targets for cefepime of greater than the MIC and free enmetazobactam concentrations of >2 mg/liter in ELF of 20% of the dosing interval, a regimen of cefepime-enmetazobactam of 2 g/0.5 g q8h i.v. infused over 2 h resulted in a probability of target attainment of ≥90% for Enterobacteriaceae with cefepime-enmetazobactam MICs of ≤8 mg/liter. This result provides a rationale to further consider cefepime-enmetazobactam for the treatment of nosocomial pneumonia caused by multidrug-resistant Enterobacteriaceae.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecção Hospitalar / Pneumonia Associada a Assistência à Saúde Tipo de estudo: Health_economic_evaluation Limite: Humans Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecção Hospitalar / Pneumonia Associada a Assistência à Saúde Tipo de estudo: Health_economic_evaluation Limite: Humans Idioma: En Revista: Antimicrob Agents Chemother Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido